GENE BY GENE LTD.

Company Snapshot

Founded: 2000
Entity Type: Private
Region: U.S.
Headquarter: Houston, Texas, U.S.
Key Geographics: North America
Corporate Address: 1445 North Loop West, Suite 820 Houston, Texas 77008 U.S. Tel. +1-713-474-2401 www.genebygene.com

Company Overview

Gene by Gene Ltd., founded in 2000, markets genetic testing services to the clinical, research and direct to consumer industries. The main platforms used include microarray and NGS.

In the clinical market, Gene by Gene operates a CLIA-certified laboratory for its clinical tests.

The company operates three business units: DNA Traits (health-based tests), DNA Findings (relationship tests such as sibling or paternity) and DNA DTC (consumer genomics).

Arpeggi, a subsidiary of Gene by Gene, is developing and marketing informatics for NGS data. The company provides a range of analytics for assisting with NGS experiments, large-scale sequencing, comparative analysis and data interpretation.

Family Tree DNA, a subsidiary of Gene by Gene, is a pioneer in the field of genetic genealogy.

In January 2021, Gene by Gene merged with MyDNA, an Australia-based DTC testing company that markets genetic wellness tests related to nutrition, fitness and skincare.

In March 2023, the company signed a partnership agreement with Verogen Inc. to boost the adoption of forensic investigative genetic genealogy.

GENE BY GENE LTD. In Reports

Next-generation Sequencing: Emerging Clinical Applications and Global Markets

Discover BCC Research's report on Next-generation Sequencing Market is steadily being integrated into clinical laboratory analysis, testing, and disease diagnostics in healthcare sectors globally.

Global DNA Sequencing: Research, Applied and Clinical Markets

BCC Research Market Report for DNA Sequencing Industry. Global market for DNA sequencing technologies and their applications in research, applied and clinical segments.

Next-generation Sequencing: Emerging Clinical Applications and Global Markets

BCC Research Market Report says clinical next-generation sequencing (NGS) should grow from $5.9 billion in 2020 to $22.9 billion by 2025 with a (CAGR) of 31.4%.

Company's Business Segments

  • Genetic Laboratory Services : This segment includes Lab Services, Next Generation Sequencing, Clinical Reporting, Research and Validation.

Applications/End User Industries

  • Exome Sequencing
  • Pharmacogenomics
  • Nutrigenomics
  • Lab Services
  • Genetic Testing
  • Tryptase Testing
AI Sentiment